Loading clinical trials...
Loading clinical trials...
Over half of chronic obstructive pulmonary disease (COPD) patients develop pulmonary hypertension. The current therapy focuses only on the basic disease and there are a lot of controversies about the use of PAH target therapy in group 3 pulmonary hypertension. Our study is to explore whether sildenafil, a pulmonary arterial hypertension (PAH) target drug, could be efficient and safe in improving symptoms and survival of severe pulmonary hypertension caused by COPD.
Age
40 - 85 years
Sex
ALL
Healthy Volunteers
No
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
June 15, 2017
Primary Completion Date
December 31, 2020
Completion Date
December 31, 2020
Last Updated
June 14, 2017
46
ESTIMATED participants
Sildenafil Citrate
DRUG
Placebo Oral Tablet
DRUG
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
NCT07073820
NCT07477600
NCT06899815
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions